Renal amyloidosis typically manifests albuminuria, nephrotic-range proteinuria, and ultimately progresses to end-stage renal failure if diagnosed late. Different types of renal amyloidosis have completely different treatments and outcomes. Therefore, amyloidosis typing is essential for disease prognosis, genetic counseling and treatment. Thirty-six distinct proteins currently known to cause amyloidosis that have been described as amyloidogenic precursors, immunohistochemistry (IHC) or immunofluorescence (IF), can be challenging for amyloidosis typing especially in rare or hereditary amyloidosis in clinical practice. We made a pilot study that optimized the proteomics pre-processing procedures for trace renal amyloidosis formalin-fixed paraffin-embedded (FFPE) tissue samples, combined with statistical and bioinformatics analysis to screen out the amyloidosis-related proteins to accurately type or subtype renal amyloidosis in order to achieve individual treatment. A sensitive, specific and reliable FFPE-based proteomics analysis for trace sample manipulation was developed for amyloidosis typing. Our results not only underlined the great promise of traditional proteomics and bioinformatics analysis using FFPE tissues for amyloidosis typing, but also proved that retrospective diagnosis and analysis of previous cases laid a solid foundation for personalized treatment.
Background and objective Alterations in DNA damage response and repair (DDR) genes produce therapeutic biomarkers. However, the significance of DDR alterations in fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) remain undefined. Here, we investigate the DDR mutational landscape of the multi-centered FH-deficient RCC cohort and examine the relationship between DDR alterations and response to immunotherapy and tyrosine kinase inhibitor (immunotherapy/TKI). Methods Genomic data and treatment outcomes were collected for patients with metastatic FH-deficient RCC. Tumors and matched blood samples from patients treated with systemic therapy were analyzed using targeted next-generation sequencing (NGS). Association between DDR mutation status and therapeutic benefit was investigated separately for immunotherapy/TKI combination therapy. Key findings and limitations A total of 105 patients were identified. Of 88 patients with successful NGS who received systemic treatment, 81 deleterious DDR gene alterations were identified in 44 DDR positive patients. Compared with DDR negative patients, DDR-positive patients had a significantly higher objective response rate (38.8% vs. 6.3%; P = 0.043), and longer median systemic treatment OS [not reached vs. 25.0 (95% CI, 13.33–36.68) months; HR, 0.149 (95% CI, 0.025–0.877); log-rank P = 0.035] with immunotherapy/TKI combination therapy. Conclusions and clinical implications The association with response to immunotherapy/TKI combination therapy demonstrated that patients with FH-deficient RCC with altered DDR genes may be rational candidates for precision treatment.